The Medicines and Healthcare products Regulatory Agency (MHRA) has launched a new study into side effects of GLP-1 medicines ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain ...

The UK’s drug regulator is to study possible serious side effects of glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro). Data from ...

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

GLP-1 medicines are licensed for Type 2 diabetes and weight management, and include the branded products Ozempic, Mounjaro ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

As the NHS rolls out Mounjaro being prescribed by GPs, weight loss jabs have been linked to potentially fatal side effects in ...

Data show that since the drugs were licensed there have been hundreds of cases of acute and chronic pancreatitis ...

Additionally, 13 cases have been linked to semaglutide, found in Wegovy and Ozempic. One death has been linked here. While ...

According to the CDC, 1 in 5 American adults is living with obesity. In recent years, many have turned to weight loss drugs ...